| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Radiology (Drs. Cotton, Jolesz, and Guttmann) and Neurology (Dr. Weiner), Brigham & Women’s Hospital, Harvard Medical School, Boston, MA.
Address correspondence and reprint requests to Dr. Charles R.G. Guttmann, Center for Neurological Imaging, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115; e-mail: guttmann{at}bwh.harvard.edu
Background: One of the diagnostic imaging hallmarks of MS is the uptake of IV administered contrast material in new lesions in the brain, signaling blood–brain barrier breakdown and active inflammation. Many clinical drug trials are designed based on the assumption that lesion enhancement on MRI remains visible on average for 1 month. For practical reasons, few serial MRI studies of patients with MS have been performed at intervals shorter than 4 weeks.
Methods: The authors performed a year-long longitudinal study in 26 patients with relapsing-remitting MS (RRMS), which comprised an initial phase of MRI follow-up at weekly intervals for 8 weeks, followed by imaging every other week for another 16 weeks, and monthly thereafter. They present a quantitative analysis (using a supervised interactive thresholding procedure) of new enhancing lesions appearing during the first 6 weeks in this cohort and evaluated from the time of first detection until enhancement was no longer seen.
Results: The average duration of Gd-DTPA enhancement in individual new lesions was 3.07 weeks (median, 2 weeks). Significant correlations were demonstrated between the duration of contrast enhancement or initial growth rates and lesion volumes. Different lesions in the same patient appeared to develop largely independent of each other and demonstrated a large range in the duration of enhancement during the acute phase of their evolution.
Conclusions: The average duration of blood–brain barrier impairment in RRMS is shorter than earlier estimates. Early lesion growth parameters may predict final lesion size. Within-patient heterogeneity of lesion evolution suggests that individual lesions develop independently.
This article has been cited by other articles:
|
|
 |
|
  M. Riva, V.N. Ikonomidou, J.J. Ostuni, P. van Gelderen, S. Auh, J.M. Ohayon, F. Tovar-Moll, N.D. Richert, J.H. Duyn, and F. Bagnato Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis-Induced Damage AJNR Am. J. Neuroradiol., August 1, 2009; 30(7): 1394 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Chen, M. O. Breckwoldt, E. Aikawa, G. Chiang, and R. Weissleder Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis Brain, April 1, 2008; 131(4): 1123 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.S. Meier, H.L. Weiner, and C.R.G. Guttmann MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1956 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Smirniotopoulos, F. M. Murphy, E. J. Rushing, J. H. Rees, and J. W. Schroeder From the Archives of the AFIP: Patterns of Contrast Enhancement in the Brain and Meninges RadioGraphics, March 1, 2007; 27(2): 525 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.H. Simon, D. Li, A. Traboulsee, P.K. Coyle, D.L. Arnold, F. Barkhof, J.A. Frank, R. Grossman, D.W. Paty, E.W. Radue, et al. Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 455 - 461. [Full Text] [PDF]
|
|
|
|
 |
|
 S Gupta, J M Solomon, T A Tasciyan, M M Cao, R D Stone, J L Ostuni, J M Ohayon, P A Muraro, J A Frank, N D Richert, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 658 - 668. [Abstract] [PDF]
|
|
|
|
|
|
A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann, W. Bruck, H. Rauschka, M. Bergmann, M. Schmidbauer, J. E. Parisi, and H. Lassmann Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain, November 1, 2005; 128(11): 2705 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minneboo, B. M. J. Uitdehaag, H. J. Ader, F. Barkhof, C. H. Polman, and J. A. Castelijns Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients Neurology, July 12, 2005; 65(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Rizvi and M. A. Agius Current approved options for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S8 - S14. [Abstract] [Full Text]
|
|
|
|
|
|
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11. [Abstract] [Full Text]
|
|
|
|
|
|
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
